ABSTRACT
The mechanism by which cholesteryl ester transfer protein (CETP) activity affects HDL metabolism was investigated using agents that selectively target CETP (dalcetrapib, torcetrapib, anacetrapib). In contrast with torcetrapib and anacetrapib, dalcetrapib requires cysteine 13 to decrease CETP activity, measured as transfer of cholesteryl ester (CE) from HDL to LDL, and does not affect transfer of CE from HDL3 to HDL2. Only dalcetrapib induced a conformational change in CETP, when added to human plasma in vitro, also observed in vivo and correlated with CETP activity. CETP-induced pre-ß-HDL formation in vitro in human plasma was unchanged by dalcetrapib ≤3 µM and increased at 10 µM. A dose-dependent inhibition of pre-ß-HDL formation by torcetrapib and anacetrapib (0.1 to 10 µM) suggested that dalcetrapib modulates CETP activity. In hamsters injected with [³H]cholesterol-labeled autologous macrophages, and given dalcetrapib (100 mg twice daily), torcetrapib [30 mg once daily (QD)], or anacetrapib (30 mg QD), only dalcetrapib significantly increased fecal elimination of both [³H]neutral sterols and [³H]bile acids, whereas all compounds increased plasma HDL-[³H]cholesterol. These data suggest that modulation of CETP activity by dalcetrapib does not inhibit CETP-induced pre-ß-HDL formation, which may be required to increase reverse cholesterol transport.
Subject(s)
Anticholesteremic Agents/pharmacology , Cholesterol Ester Transfer Proteins/metabolism , Cholesterol/metabolism , High-Density Lipoproteins, Pre-beta/metabolism , Amides , Animals , Bile Acids and Salts/metabolism , Binding Sites , Biological Transport/drug effects , Cholesterol/blood , Cholesterol Ester Transfer Proteins/blood , Cricetinae , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Esters , High-Density Lipoproteins, Pre-beta/blood , Humans , Oxazolidinones/pharmacology , Quinolines/pharmacology , Sulfhydryl Compounds/pharmacologyABSTRACT
A series of tetrahydro-cyclopenta[b]indoles modulating the activity of the liver-X-receptor (LXR) were derived from a high throughput screening hit. The potency and selectivity for LXRbeta versus LXRalpha was improved. One compound, administered to wild-type mice modestly increased plasma HDL-cholesterol with no change in plasma triglycerides (TG) and reduced effects on liver TG content compared to T0901317. This novel series of LXR agonists shows promise to improve therapeutic efficacy with reduced potential to increase TG.
Subject(s)
Chemistry, Pharmaceutical/methods , DNA-Binding Proteins/chemistry , Indoles/chemical synthesis , Receptors, Cytoplasmic and Nuclear/chemistry , Animals , Cholesterol, HDL/metabolism , Drug Design , Hydrocarbons, Fluorinated/pharmacology , Indoles/pharmacology , Inhibitory Concentration 50 , Liver X Receptors , Male , Mice , Mice, Inbred C57BL , Models, Chemical , Orphan Nuclear Receptors , Sulfonamides/pharmacology , Transcriptional Activation , Triglycerides/metabolismABSTRACT
A series of branched and unbranched anilinohexafluoroisopropanols related to the known sulfonamide T0901317 were prepared and evaluated as activators/modulators of both LXRalpha and LXRbeta. A structure-activity relationship was established and compounds with high potency on both the receptors were identified. Many compounds showed a tendency toward selectivity for LXRbeta versus LXRalpha. Several analogues were evaluated for effects on plasma lipoprotein levels in mice. A few of these significantly raised HDL-cholesterol levels in plasma but showed markedly different effects on liver triglyceride content, suggesting that this series may yield candidates with improved efficacy/safety profiles compared to existing molecules.
Subject(s)
Aniline Compounds/chemical synthesis , DNA-Binding Proteins/drug effects , Receptors, Cytoplasmic and Nuclear/drug effects , Aniline Compounds/pharmacokinetics , Aniline Compounds/pharmacology , Animals , Atherosclerosis/drug therapy , Cholesterol, HDL/blood , Lipoproteins/blood , Liver , Liver X Receptors , Male , Mice , Mice, Inbred C57BL , Orphan Nuclear Receptors , Propanols/chemical synthesis , Propanols/pharmacokinetics , Propanols/pharmacology , Structure-Activity Relationship , Transcriptional Activation/drug effects , Triglycerides/bloodABSTRACT
Endothelin-1 (ET-1) is mitogenic and/or antiapoptotic in human cancers, and antagonists to ET-1 receptors are under evaluation for cancer treatment. Inhibition of ET-1 activation by the endothelin-converting enzymes 1(a)(-)(d) (ECE-1(a)(-)(d); EC 3.4.24.71) represents another approach to block the ET-1 effect in cancer. To evaluate this potential, we synthesized and characterized a series of low nanomolar nonpeptidic thiol-containing ECE-1 inhibitors, and evaluated their effect, as well as the effect of inhibitors for the related metalloproteases neprilysin (NEP; EC 3.4.24.11) and angiotensin-converting enzyme (ACE; EC 3.4.15.1), on human glioblastoma cell growth. Only ECE-1 inhibitors inhibited DNA synthesis by human glioblastoma cells. Exogenous addition of ET-1 or bigET-1 to glioblastoma cells did not counterbalance the growth inhibition elicited by ECE-1 inhibitors, suggesting that ECE-1 inhibitors block the proliferation of human glioblastoma cells most likely via a mechanism not involving extracellular production of ET-1. This class of molecules may thus represent novel therapeutic agents for the potential treatment of human cancer.
Subject(s)
Antineoplastic Agents/chemical synthesis , Aspartic Acid Endopeptidases/antagonists & inhibitors , Sulfhydryl Compounds/chemical synthesis , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Carbamates/chemical synthesis , Carbamates/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Central Nervous System Neoplasms , Drug Screening Assays, Antitumor , Endothelin-1/pharmacology , Endothelin-Converting Enzymes , Glioblastoma , Humans , Hydrazines/chemical synthesis , Hydrazines/chemistry , Metalloendopeptidases , Proline/analogs & derivatives , Proline/chemical synthesis , Proline/chemistry , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Pyrrolidines/chemical synthesis , Pyrrolidines/chemistry , Structure-Activity Relationship , Sulfhydryl Compounds/chemistry , Sulfhydryl Compounds/pharmacologyABSTRACT
We tested the hypothesis that endothelin-converting enzyme (ECE) inhibition ameliorates end-organ damage in rats harboring both human renin and human angiotensinogen genes (dTGR). Hypertension develops in the animals, and they die by age 7 weeks of heart and kidney failure. Three groups were studied: dTGR (n=12) receiving vehicle, dTGR receiving ECE inhibitor (RO0687629; 30 mg/kg by gavage; n=10), and Sprague-Dawley control rats (SD; n=10) receiving vehicle, all after week 4, with euthanasia at week 7. Systolic blood pressure was not reduced by ECE inhibitor compared with dTGR (205+/-6 versus 206+/-6 mm Hg at week 7, respectively). In contrast, ECE inhibitor treatment significantly reduced mortality rate to 20% (2 of 10), whereas untreated dTGR had a 52% mortality rate (7 of 12). ECE inhibitor treatment ameliorated cardiac damage and reduced left ventricular ECE activity below SD levels. Echocardiography at week 7 showed reduced cardiac hypertrophy (4.8+/-0.2 versus 5.7+/-0.2 mg/g, P<0.01) and increased left ventricular cavity diameter (5.5+/-0.3 versus 3.1+/-0.1 mm, P<0.001) and filling volume (0.42+/-0.04 versus 0.16+/-0.06 mL, P<0.05) after ECE inhibitor compared with untreated dTGR. ECE inhibitor treatment also reduced cardiac fibrosis, tissue factor expression, left ventricular basic fibroblast growth factor mRNA levels, and immunostaining in the vessel wall, independent of high blood pressure. In contrast, the ECE inhibitor treatment showed no renoprotective effect. These data are the first to show that ECE inhibition reduces angiotensin II-induced cardiac damage.
